Treatment of alopecia areata: An Australian expert consensus statement.
가이드라인
5/5 보강
TL;DR
The purpose of this consensus statement is to outline a treatment algorithm for AA, including the indications for systemic treatment, appropriate choice of systemictreatment, satisfactory outcome measures and when to discontinue successful or unsuccessful treatment.
📑 코퍼스 인용 관계
· 인용됨 65
📑 인용한 논문 (6) ▾
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Area… American journal of clinical dermatology · 2026
- Mechanism of PPARα agonist in alopecia areata. American journal of translational research · 2025
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata. Balkan medical journal · 2025
- Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005%… Indian dermatology online journal · 2025
- Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RN… Clinical, cosmetic and investigational dermatology · 2025
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies. MedComm · 2025
연도별 인용 (2012–2026) · 합계 171
OpenAlex 토픽 ·
Hair Growth and Disorders
Autoimmune Bullous Skin Diseases
Dermatologic Treatments and Research
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
원형 탈모증(alopecia areata, AA)의 표준화된 치료 알고리즘이 부재한 상황에서, 호주 전문가 합의를 통해 전신 치료의 적응증, 약제 선택, 결과 평가 및 치료 중단 시점을 제시하기 위함입니다.
【방법】
호주 피부과 전문가들의 합의문(consensus statement) 형식으로, 국소·병변내·전신 치료제에 대한 기존 근거를 검토하고 임상에서 적용 가능한 치료 알고리즘을 도출하였습니다.
【주요 결과】
경증 AA에서는 국소 스테로이드, 미녹시딜(minoxidil), 국소 면역요법이 활용되며, 전신 치료의 적응증으로 ▲급속한 탈모 진행 ▲광범위 탈모(≥50%) ▲만성 경과 ▲심한 심리적 고통 등이 제시되었습니다. 전신 치료 옵션으로는 글루코코르티코이드, 메토트렉세이트, 사이클로스포린, 아자치오프린, 답손, mycophenolate mofetil, 타크로리무스, 설파살라진이 포함됩니다. 자연 관해율은 단발성 패치의 경우 40%(6개월 이내), 다발성도 27%는 12개월 이내 관해되나, 33%는 만성으로 진행합니다.
【임상적 시사점 (성형외과 의사 관점)】
모발이식이나 두피(scalp) 관련 상담 시 환자가 AA로 의심된다면, 활동성 병변에 대한 외과적 개입은 재발·확산 위험이 있어 피하고 피부과적 약물치료를 우선 의뢰하는 것이 안전합니다. 특히 급속 진행형이나 50% 이상 광범위 탈모, 눈썹·속눈썹 침범 사례는 미용 시술(문신·이식) 전 반드시 전신치료를 통한 안정화 단계를 확인해야 하며, 심리적 고통이 큰 환자에서는 다학제적 접근을 고려해야 합니다.
Alopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6 months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop alopecia totalis and 15% will develop alopecia universalis. The unpredictable course and psychological distress attributable to AA contributes to the illness associated with AA. Numerous topical, intralesional and systemic agents are currently used to treat AA; however, there is a paucity of data evaluating their use, effectiveness and tolerability. Topical therapy, including topical glucocorticosteroids, minoxidil and immunotherapy, can be used in cases of limited disease. There are no universally agreed indications for initiating systemic treatment for AA. Possible indications for systemic treatment include rapid hair loss, extensive disease (≥50% hair loss), chronic disease, severe distress or a combination of these factors. Currently available systemic treatments include glucocorticosteroids, methotrexate, ciclosporin, azathioprine, dapsone, mycophenolate mofetil, tacrolimus and sulfasalazine. The optimal treatment algorithm has not yet been described. The purpose of this consensus statement is to outline a treatment algorithm for AA, including the indications for systemic treatment, appropriate choice of systemic treatment, satisfactory outcome measures and when to discontinue successful or unsuccessful treatment.
【연구 목적】 원형 탈모증(alopecia areata, AA)의 표준화된 치료 알고리즘이 부재한 상황에서, 호주 전문가 합의를 통해 전신 치료의 적응증, 약제 선택, 결과 평가 및 치료 중단 시점을 제시하기 위함입니다.
APA 7
Cranwell, W. C., Lai, V. W., Photiou, L., Meah, N., Wall, D., Rathnayake, D., Joseph, S., Chitreddy, V., Gunatheesan, S., Sindhu, K., Sharma, P., Green, J., Eisman, S., Yip, L., Jones, L., & Sinclair, R. (2019). Treatment of alopecia areata: An australian expert consensus statement.. The Australasian journal of dermatology, 60(2), 163-170. https://doi.org/10.1111/ajd.12941
Vancouver
Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: An Australian expert consensus statement. Aust. jour. derm.. 2019;60(2):163-170. doi:10.1111/ajd.12941
AMA 11
Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: An Australian expert consensus statement. Aust. jour. derm.. 2019;60(2):163-170. doi:10.1111/ajd.12941
Chicago
Cranwell, W. C., Lai, V. W., Photiou, L., Meah, N., Wall, D., Rathnayake, D., Joseph, S., Chitreddy, V., Gunatheesan, S., Sindhu, K., and .... 2019. "Treatment of alopecia areata: An Australian expert consensus statement." The Australasian journal of dermatology 60 (2): 163-170. https://doi.org/10.1111/ajd.12941
MLA 9
Cranwell, W. C., et al. "Treatment of alopecia areata: An Australian expert consensus statement." The Australasian journal of dermatology, vol. 60, no. 2, 2019, pp. 163-170. doi:10.1111/ajd.12941.
PMID
30411329 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 해부 | scalp
|
두피 | dict | 1 | |
| 해부 | scalp
|
두피 | dict | 1 | |
| 해부 | scalp
|
두피 | dict | 1 | |
| 약물 | minoxidil
|
미녹시딜 | dict | 1 | |
| 약물 | minoxidil
|
미녹시딜 | dict | 1 | |
| 약물 | minoxidil
|
미녹시딜 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
- Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunctio…
- Pathomechanisms of immune-mediated alopecia.
- The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implicatio…
- Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework.
- Baricitinib for the Treatment of Alopecia Areata.
- Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatm…
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Dis…
- An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options.
- Hair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point.
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.
- Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review.
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopec…
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023).
- Study of the Thyroid Profile of Patients with Alopecia.
- Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
- Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover …
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLE…
같은 제1저자의 인용 많은 논문 (5)
- Sunscreen and facial skincare products in frontal fibrosing alopecia: a case-control study.
- Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation.
- Frontal fibrosing alopecia: Regrowth following cessation of sunscreen on the forehead.
- Loose anagen hair syndrome: Treatment with systemic minoxidil characterised by marked hair colour change.
- Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Minoxidil and its use in hair disorders: a review.
TL;DRThis article aims to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical minoxidil.